Literature DB >> 8363252

Immunomodulating activity of antifungal drugs.

H Yamaguchi1, S Abe, Y Tokuda.   

Abstract

1. The immunomodulating activity of antifungal drugs was reviewed. Although results are conflicting, all azole drugs tend to be immunosuppressive, except for fluconazole, which has no immunologic effect. In contrast, the polyene antibiotic amphotericin B (AMPH) is immunostimulatory. 2. AMPH induced host resistance to Pseudomonas aeruginosa infection in mice, whereas no azole drugs did so. 3. Polymorphonuclear leukocytes are activated by AMPH, but not by any azole drugs, in terms of the level of their adherence. 4. No azole drugs induce in vitro tumor necrosis factor alpha (TNF) production by macrophages, whereas AMPH slightly but substantially does so. 5. AMPH potently primes macrophages in vitro and in vivo so that they produce large amounts of TNF after the secondary stimulation (triggering) by bacterial lipopolysaccharides or a streptococcal preparation used for antitumor immunotherapy, OK432. 6. Viable or heat-killed Candida albicans cells are capable of inducing in vitro TNF production by macrophages. This activity of the fungal cells is enhanced by AMPH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363252     DOI: 10.1111/j.1749-6632.1993.tb35905.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

1.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 3.  Macrophages in resistance to candidiasis.

Authors:  A Vázquez-Torres; E Balish
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

4.  Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.

Authors:  Oscar Zaragoza; Coralia Mihu; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.

Authors:  Emmanuel Roilides; Caron A Lyman; Joanna Filioti; Onome Akpogheneta; Tin Sein; Cristina Gil Lamaignere; Ruta Petraitiene; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 8.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations.

Authors:  J D Nosanchuk; W Cleare; S P Franzot; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.

Authors:  Lloyd W Turtinen; David N Prall; Lindsay A Bremer; Rachel E Nauss; Scott C Hartsel
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.